Abstract
When a new psychotropic drug is introduced on the market with claims that it acts more specifically than the previous ones this has to be proven - not just in in vitro receptor binding systems and animal experiments - but also in patients. That can only be done by properly designed clinical studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Ahtee L, Mattila MJ, Vapaatalo HI (1967) The binding of some phenothiazines to human serum in vitro. Biochem Pharmacol 16: 2432–2435
Alfredsson G, Lindberg M, Sedvall G (1982) The presence of 7-hydroxychlorpromazine in CSF of chlorpromazine-treated patients. Psychopharmacology (Berlin) 77: 376–378
Alfredsson G, Harnryd C, Wiesel F-A (1984) Effects of sulpiride and ehlorpromazine on depressive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology (Berlin) 84: 237–241
Alfredsson G, Harnryd C, Wiesel FA (1985) Effects of sulpiride and ehlorpromazine on autistic and positive symptoms in schizophrenic patients - relationship to drug concentrations. Psychopharmacology (Berlin) 85: 8–13
Balant-Gorgia AE, Eisele R, Balant L, Garrone G (1984) Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. Eur Arch Psychiatr Neurol Sci 234: 1–4
Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ (1985) Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study. Psychopharmacol Bull 21: 66–68
Bolvig Hansen L, Larsen N-E (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berlin) 87: 16–19
Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berlin) 78: 112–115
Brown WA, Silver MA (1985) Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. J Clin Psychopharmacol 5: 143–147
Calil HM, Avery DH, Hollister LE, Creese I, Snyder SH (1979) Serum levels of neuroleptics measured by dopamine radio receptor assay and some clinical observations. Psychiatry Res 1:39— 44
Cohen BM, Lipinski JF, Harris PQ, Pope HG, Friedman M (1980 a) Clinical use of the radioreceptor asssay for neuroleptics. Psychiatry Res 1: 173–178
Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI (1980 b) Neuroleptic blood levels and therapeutic effect. Psychopharmacology (Berlin) 70: 191–193
Cross AJ, Crow TJ, Owen F (1981) 3H-Flupenthixol binding in post-mortem brains of schizophrenics: Evidence for a selective increase in dopamine D2 receptors. Psychopharmacology (Berlin) 74: 122–124
Csernansky JG, Kaplan J, Holman CA, Hollister LE (1983) Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berlin) 81: 115–118
Dahl SG (1976) Pharmacokinetics of methotrimeprazine after single and multiple doses. Clin Pharmacol Ther 19: 435–442
Dahl SG (1981) Pharmacokinetic aspects of new antipsychotic drugs. Neuropharmacology 20: 1299–1302
Dahl SG (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 4: 33–40
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 11: 36–61
Dahl SG, Hall H (1981) Binding affinity of levomepromazine and two of its major metabolites to central dopamine and adrenergic receptors in the rat. Psychopharmacology (Berlin) 74: 101–104
Dahl SG, Strandjord RE (1977) Pharmacokinetics of ehlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448
Davis JM, Ericksen SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R (1985) Haloperidol plasma levels and clinical response: basic concepts and clinical data. Psychopharmacol Bull 21: 48–51
Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM (1981) Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology (Berlin) 73: 205–210
Freedberg KA, Innis RB, Creese I, Snyder SH (1979) Antipsychotic drugs: differential plasma protein binding and therapeutic activity. Life Sci 24: 2467–2474
Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML (1984) Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 4: 133–137
Hals PA, Hall H, Dahl SG (1986) Phenothiazine drug metabolites: Dopamine D2 receptor, α1 and α2-adrenoceptor binding. Eur J Pharmacol 125: 373–381
Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient Compliance. Futura Mount Kisco, New York, pp 123–152
Jorgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111–174
Kirch DG, Bigelow LB, Wyatt RJ (1985) The interpretation of plasma haloperidol concentrations. Arch Gen Psychiatry 42: 838–836
Krieglstein J, Lier F, Michaelis J (1972) Albumin binding and hydrophobic character of promazine and chlorpromazine metabolites. Arch Pharmacol 272: 121–130
Kucharski LT, Alexander P, Tune L, Coyle J (1984) Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. Psychopharmacology (Berlin) 82: 194–198
Larsson M, Axelsson R, Forsman A (1984) On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate. Curr Therapeutic Res 36: 1071–1088
Lindenmayer JP, Smith D, Katz I (1984) Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. J Clin Psychiatry 45: 117–119
Linkowski P, Houbain P, Von Frenckell R, Mendlewicz J (1984) Haloperidol plasma levels and clinical response in paranoid schizophrenics. Eur Arch Psychiatr Neurol Sci 234: 231–236
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1983) Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berlin) 81: 354–356
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 a) Therapeutic blood levels of fluphenazine: Plasma or RBC determinations? Psychopharmacol Bull 20: 168–170
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 b) Fluphenazine plasma levels and clinical response. J Clin Psychiatry 45: 370–373
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL (1984 c) Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol 4: 155–157
Mavroidis ML; Garver DL, Kanter DR, Hirschowitz J (1985) Plasma haloperidol levels and clinical response: confounding variables. Psychopharmacol Bull 21: 62–65
Meitzer HY, Busch DA, Fang VS (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271–283
Newman DC, Epperly M, Sangarasivam S, Maruta T, Homburger HA (1984) Neuroleptic levels in serum: clinical usefulness in schizophrenic patients. Clin Res 32:741 A
Richelson E, Nelson A (1984) Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 103: 197–204
Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R (1985) Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 21: 59–61
Silverstone T, Cookson J, Ball R, Chin CN, Jacobs D, Lader S, Gould S (1984) The relationship of dopamine receptor blockade to clinical response in schizophrenic patients treated with pimozide or haloperidol. J Psychiatry Res 18: 255–268
Smith RC, Vroulis G, Misra CH, Schoolar J, De John C, Korivi P, Leelavahti DE, Arzu D (1980) Receptor techniques in the study of plasma levels of neuroleptics and antidepressant drugs. Commun Psychopharmacol 4: 451–465
Smith RC, Baumgartner R, Misra CH, Mauldin M, Shvartsburd A, Ho BT, De John C (1984 a) Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays. Arch Gen Psychiatry 41: 1044–1049
Smith RC, Baumgartner R, Ravichandran GK, Shvartsburd A, Schoolar JC, Allen P, Johnson R (1984 b) Plasma and red cell levels of thioridazine and clinical response in schizophrenia. Psychiatry Res 12: 287–296
Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M (1985) Haloperidol and thioridazine drug levels and clinical response in schizophrenia: comparison of gas-liquid chromatography and radioreceptor drug level assays. Psychopharmacol Bull 21: 52–58
Tang SW, Glaister J, Davidson L, Toth R, Jeffries JJ, Seeman P (1984) Total and free plasma neuroleptic levels in schizophrenic patients. Psychiatry Res 13: 285–293
Tune LE, Creese I, De Paulo JR, Slavney PR, Coyle JT, Snyder SH (1980) Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. Am J Psychiatry 137: 187–190
Tune LE, Creese I, De Paulo JR, Slavney PR, Snyder SH (1981) Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenia. J Nerv Ment Dis 169: 60–63
Van Putten T, May PRA, Jenden DJ (1981) Does a plasma level of chlorpromazine help? Psychol Med 11: 729–734
Van Putten T, May PRA, Marder SR, Wilkins JN, Rosenberg BJ (1983) Plasma levels of thiothixene by radioreceptor assay: clinical usefulness. Psychopharmacology (Berlin) 79: 40–44
Van Putten T, Marder SR, May PRA, Poland RE, O’Brien RP (1985 a) Plasma levels, haloperidol and clinical response. Psychopharmacol Bull 21: 69–72
Van Putten T, Marder SR, Mintz (1985 b) Plasma haloperidol levels: clinical response and fancy mathematics. Arch Gen Psychiatry 42: 835
Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology (Berlin) 73: 55–62
Wode-Helgodt B, Borg S, Fyrö B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 58: 149–173
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Dahl, S.G., Hals, PA. (1987). Pharmacokinetic and Pharmacodynamic Factors Causing Variability in Response to Neuroleptic Drugs. In: Dahl, S.G., Gram, L.F., Paul, S.M., Potter, W.Z. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71288-3_31
Download citation
DOI: https://doi.org/10.1007/978-3-642-71288-3_31
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71290-6
Online ISBN: 978-3-642-71288-3
eBook Packages: Springer Book Archive